Metabolic
CagriSema
Also called Semaglutide + cagrilintide, Cagrilintide/semaglutide 2.4/2.4
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Quick start
CagriSema at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 0.5–4.8 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
What one draw delivers
| Component | Share | Per draw |
|---|---|---|
| Semaglutide | 50% | 250 mcg |
| Cagrilintide | 50% | 250 mcg |
Every draw has these same proportions.
0.5–4.8 mg of CagriSema per administration, worked out from the components rather than quoted from a study of the blend.
A fixed-ratio blend of semaglutide and cagrilintide sold as one vial, so it is drawn as a whole. The two clear at different multi-day rates, so no single half-life is given and the decay view plots both components. The range here is worked out from the components rather than quoted as one figure: escalation mirrors semaglutide's weekly steps to a combined 2.4 mg + 2.4 mg. Its components are covered on their own pages.
What is in a 4.8 mg CagriSema vial
| Component | Share | Per vial |
|---|---|---|
| Semaglutide | 50% | 2.4 mg |
| Cagrilintide | 50% | 2.4 mg |
Every draw has these same proportions.
Dosing schedule
How CagriSema is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Semaglutide + cagrilintide; conservative start to limit gastrointestinal effects. | 0.25 mg + 0.25 mg | Once weekly | SubQ |
| Weeks 5–8 | 0.5 mg + 0.5 mg | Once weekly | SubQ |
| Weeks 9–12 | 1.0 mg + 1.0 mg | Once weekly | SubQ |
| Weeks 13–16 | 1.7 mg + 1.7 mg | Once weekly | SubQ |
| Week 17+Target combined step; step up no sooner than every 4 weeks. | 2.4 mg + 2.4 mg | Once weekly | SubQ |
Modelled level — once a week
One curve per component: the components clear at very different rates.
Where these numbers come from
- REDEFINE 1 (Novo Nordisk phase-3 obesity program)Once-weekly semaglutide 2.4 mg co-formulated with cagrilintide 2.4 mg (CagriSema) escalated over 16 weeks in adults with obesity.
- Component sourcesSee the semaglutide and cagrilintide pages for the individual components' trials.